Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza virus vaccine live intranasal (quadrivalent) - AstraZeneca

Drug Profile

Influenza virus vaccine live intranasal (quadrivalent) - AstraZeneca

Alternative Names: Fluenz Tetra; Flumist; FluMist Quadrivalent; Influenza vaccine live-intranasal (quadrivalent) - AstraZeneca; MEDI-3250; MEDI-8662; Q-LAIV Flu Vac; Q-LAIV Flu Vaccination; Q-LAIV-AstraZeneca; Q-LAIV-BFS-AstraZeneca; Q/LAIV; Q/LAIV-AstraZeneca; Q/LAIV-BFS-AstraZeneca; Quadrivalent live attenuated influenza vaccine - AstraZeneca; Quadrivalent live attenuated influenza virus vaccine - AstraZeneca; VN-0107

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune
  • Developer AstraZeneca; Japan Vaccine
  • Class Influenza virus vaccines live
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 24 Oct 2023 FDA assigns PDUFA action date of 31/03/2024 (first quarter of 2024)for self- or caregiver-administered option for Influenza virus vaccine live intranasal for the prevention of Influenza virus infections
  • 24 Oct 2023 AstraZeneca plans to launch the self- or caregiver-administered option for Influenza virus vaccine in the US for the 2024/2025 flu season
  • 24 Oct 2023 The US FDA accepts sBLA for the approval of a self- or caregiver-administered option for intranasal influenza virus vaccine live intranasal for Influenza virus infections for review
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top